MarrieRAFiskJDFitzgeraldK, et al. Etiology, effects and management of comorbidities in multiple sclerosis: recent advances. Front Immunol2023; 14: 1197195.
2.
KonenFFMöhnNWitteT, et al. Treatment of autoimmunity: the impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. Autoimmun Rev2023; 22(5): 103312.
3.
BoeschMBatyFRassouliF, et al. What is disease modification and is this concept even helpful. Eur J Intern Med2024; 124: 1–4.
4.
FrankHAChaoMTremlettH, et al. Comorbidities and their association with outcomes in the multiple sclerosis population: a rapid review. Mult Scler Relat Disord2024; 92: 105943.
5.
AltmanNKrzywinskiM. Association, correlation and causation. Nat Methods2015; 12: 899–900.
6.
YangFHuTHeK, et al. Multiple sclerosis and the risk of cardiovascular diseases: a Mendelian randomization study. Front Immunol2022; 13: 861885.
7.
ChatawayJWilliamsTBlackstoneJ, et al. Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2 trial): a multicentre, randomised placebo-controlled, double-blind, phase 3 clinical trial. ECTRIMS 2024 – late breaking oral presentations. Mult Scler J2024; 30(suppl 3): 1138–1147.
8.
SolaroCGamberiniGMasuccioFG. Depression in multiple sclerosis: epidemiology, aetiology, diagnosis and treatment. CNS Drugs2018; 32(2): 117–133.
9.
FiestKMWalkerJRBernsteinCN, et al. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Mult Scler Relat Disord2016; 5: 12–26.
10.
GasimMBernsteinCNGraffLA, et al. Adverse psychiatric effects of disease-modifying therapies in multiple sclerosis: a systematic review. Mult Scler Relat Disord2018; 26: 124–156.
